PC
CALA

Polar Capital’s Calithera Biosciences, Inc CALA Stock Holding History

Polar Capital’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-25,000
Closed -$2.22M – 330
2020
Q1 		$2.22M Buy
+25,000
New +$2.98M 0.02% 242

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital's CALA Position: Q2 2020 in Review

Polar Capital sold out of Calithera Biosciences, Inc (CALA) in Q2 2020, closing a stake of 25,000 shares — an estimated $2.22M sold.

Polar Capital first reported a position in CALA in Q1 2020 and held it in 1 quarter. The position peaked at $2.22M in Q1 2020. 110 funds tracked by Wall St. Rank hold CALA as of Q2 2020.

  • Polar Capital reported no remaining Calithera Biosciences, Inc position as of Q2 2020 after selling out during the quarter.
  • Polar Capital sold 25,000 Calithera Biosciences, Inc shares in Q2 2020, an estimated $2.22M.
  • Polar Capital first reported a position in Calithera Biosciences, Inc in Q1 2020 and held it in 1 quarter.
  • Polar Capital's Calithera Biosciences, Inc position peaked at $2.22M in Q1 2020.
  • 110 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2020.

Based on Polar Capital's 13F filing for Q2 2020, filed 14 Aug 2020.